Office For Life Sciences
The Life Sciences Innovative Manufacturing Fund (LSIMF) Phase 2 is now closed to new applications.
Background and objectives of the programme
The Life Sciences Innovative Manufacturing Fund (LSIMF) is part of the Global Britain Investment Fund and will provide 60 million in capital grants for investment in the manufacture of:
- human medicines (drug substance and drug product)
- medical diagnostics
- MedTech products
We have already announced the first tranche of companies to be supported by LSIMF and are now re-opening the fund with the remaining budget of 7.6 million.
Specific themes
We particularly welcome applications from companies with manufacturing investments that demonstrate the adoption of innovative process technologies, for example:
- flexible manufacturingenabling rapid product switching
- continuous manufacturing
- technologies that willminimise impact of the product or the manufacturing process on the environment
- digital twins, which harness the power of data analytics and modelling to optimise manufacturing processes
This list is not exhaustive.
Fund objectives
We will prioritise applicants based on their alignment to the funds objectives:
1.Creating economic opportunity through investments that will provide high-wage, high-skilled jobs.
2.Deploying cutting-edge innovations (at both pilot and commercial scale) which can be embedded in either the product itself or the manufacturing process.
3.Increasing health resilience, either through increased domestic capacity or by providing flexible capabilities that can be re-deployed in some way in a future health emergency.
4.Minimising impact on the environment, which might include reduction in input resources or using alternative input materials to become more sustainable or support the governments net zero target.
Contact
Contact the LSIMF support team if you have any queries about the fund: LSIMF@officeforlifesciences.gov.uk.